Ketamine and belief updating: Neurocognitive mechanisms in the treatment of major depressive disorder. – KETABELIEF
Major depressive disorder is a debilitating disease. Despite its significance, the neurocognitive mechanisms involved in clinical remission remain mysterious. One out of three patients does not respond to monoaminergic treatments, leading to the diagnosis of treatment-resistant depression (TRD). Here we aim to identify and specify the mechanisms of a novel, fast-acting antidepressant treatment strategy consisting of subanesthetic ketamine infusions in TRD patients. We will combine behavioral testing of biases in belief updating and emotion processing with a pharmacological challenge comparing early and tardive effects of ketamine to monoaminergic antidepressants. Functional magnetic resonance imaging and computational modeling will provide further insights into the neurocomputational mechanisms of ketamine action. Findings will provide first-time insights into how ketamine improves clinical symptoms, and offer new perspectives for the treatment of mood disorders.
Project coordination
Liane SCHMIDT (Institut du cerveau et de la moelle épinière)
The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.
Partner
ICM Institut du cerveau et de la moelle épinière
Help of the ANR 241,024 euros
Beginning and duration of the scientific project:
March 2022
- 36 Months